Hostname: page-component-745bb68f8f-grxwn Total loading time: 0 Render date: 2025-01-22T11:48:19.507Z Has data issue: false hasContentIssue false
  • English
  • Français

Safety, Not Only Efficacy Still to be Proven for Controversial New MS Treatment

Published online by Cambridge University Press:  18 February 2016

Marcelo Kremenchutzky
Marcelo Kremenchutzky*
Affiliation:
London Health Sciences Centre London, Ontario, Canada
Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Editorial
Information
Canadian Journal of Neurological Sciences , Volume 38 , Issue 5 , September 2011 , pp. 667 - 668
Copyright
Copyright © Canadian Neurological Sciences Federation 2011

References

1.Smith, CM. Origin and uses of primum non nocere - above all, do no harm! J Clin Pharmacol. 2005;45(4):371–7.CrossRefGoogle ScholarPubMed
2.Kremenchutzky, M, Walt, L. Lack of congruence in the ratings of patients' health status by patients with MS and their physicians. Neurology. 2010;74(9) Suppl 2:A364.Google Scholar
3.Burton, JM, Alikhani, K, Goyal, M, et al. Complications in MS patients after CCSVI procedures abroad (Calgary, AB). Can J Neurol Sci. 2011;38(5):741–6.CrossRefGoogle ScholarPubMed
4.Zamboni, P, Galeotti, R, Menegatti, E, et al. A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg. 2009;50:1348–58.CrossRefGoogle ScholarPubMed
5.Samson, K. Experimental multiple sclerosis vascular shunting procedure halted at Stanford. Ann Neurol. 2010;67:A13–15.Google Scholar
6.Ludyga, T, Kazibudzki, M, Simka, M, et al. Endovascular treatment for chronic cerebrospinal venous insufficiency: is the procedure safe? Phlebology. 2010;25(6):286–95.CrossRefGoogle Scholar
7.Petrov, I, Grozdinski, L, Kaninski, G, et al. Safety profile of endovascular treatment for chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Endovasc Ther. 2011;18:314–23.CrossRefGoogle ScholarPubMed
8.www.fda.gov [homepage on the Internet]. What is a serious adverse event? [updated 2011 Jun 23; cited 2011 Jun 30]. Available from: http://www.fda.gov/safety/medwatch/howtoreport/ucm 053087.htm.Google Scholar